APA (7th ed.) Citation

MT, B., L, G., E, G., SH, P., B, M., TJ, S., . . . M, S. (2025). Nivolumab plus cabozantinib in metastatic renal cell carcinoma: Real-world evidence from the international ARON-1 study. Frontiers in oncology, 15, 1605282. https://doi.org/10.3389/fonc.2025.1605282

Chicago Style (17th ed.) Citation

MT, Bourlon, et al. "Nivolumab Plus Cabozantinib in Metastatic Renal Cell Carcinoma: Real-world Evidence from the International ARON-1 Study." Frontiers in Oncology 15 (2025): 1605282. https://doi.org/10.3389/fonc.2025.1605282.

MLA (9th ed.) Citation

MT, Bourlon, et al. "Nivolumab Plus Cabozantinib in Metastatic Renal Cell Carcinoma: Real-world Evidence from the International ARON-1 Study." Frontiers in Oncology, vol. 15, 2025, p. 1605282, https://doi.org/10.3389/fonc.2025.1605282.